Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Immunoinformatics Prediction of an Epitope Based Peptide Vaccine for Neisseria Gonorrhea Dihydrolipoamide Acetyltransferase Protein

Version 1 : Received: 6 January 2021 / Approved: 8 January 2021 / Online: 8 January 2021 (10:50:36 CET)

How to cite: Elhag, M.; Osama Sati, A.; H. Abdelmoneim, A.; Mohammed Saadaldin, M.; Salah Taha, T.; A.Hassan, M. Immunoinformatics Prediction of an Epitope Based Peptide Vaccine for Neisseria Gonorrhea Dihydrolipoamide Acetyltransferase Protein. Preprints 2021, 2021010141 (doi: 10.20944/preprints202101.0141.v1). Elhag, M.; Osama Sati, A.; H. Abdelmoneim, A.; Mohammed Saadaldin, M.; Salah Taha, T.; A.Hassan, M. Immunoinformatics Prediction of an Epitope Based Peptide Vaccine for Neisseria Gonorrhea Dihydrolipoamide Acetyltransferase Protein. Preprints 2021, 2021010141 (doi: 10.20944/preprints202101.0141.v1).

Abstract

Sexually transmitted infections (STIs) such as Gonorrhea is associated with serious morbidity and mortality rates in the world considering the multiple virulence factors possessed. The disease is manifested as salpingitis, pelvic inflammatory disease (PID), and bacteremia and is controlled by macrophages, dendritic cells, neutrophils, T cells, epithelial cells and cytokines. Dihydroliponamide acetyltransferase, a component of the mitochondrial pyruvate complex can be used as immunogenic target. Recent changes in the strain allowed the bacteria to acquire resistance against antibiotics.Vaccination remains an alternative to prevention against the disease. This study predicts an effective epitope-based vaccine against dihydrolipoamide acetyltransferase of Neisseria Gonorrhea using immunoinformatics approaches. Sequences retrieved from NCBI were passed on several prediction tests to analyze for possible B-cell, T-cell MHC class I epitopes and class II. Two epitopes showed high binding affinity for B-cells, while thirteen epitopes showed high binding affinity for MHCI and forty-five for MHCII. A population coverage of 100% for combined MHC I and II dictates the huge number of individuals who will benefit from formulating the vaccine. We recommend invivo and invitro studies to prove our prediction results.

Subject Areas

Immunoinformatics; Neisseria Gonorrhea; Dihydroliponamide Acetyltransferase; Peptide vaccine; Epitope

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.